The road ahead for stem cell therapies in type 1 diabetes

AIMS: Type 1 diabetes results from autoimmune destruction of insulin-producing pancreatic β-cells. Although exogenous insulin remains the standard treatment, it does not restore physiological glucose regulation. Differentiation of human pluripotent stem cells into β-cells offers a scalable alternative to cadaveric islet transplantation and has progressed rapidly over the past decade, resulting in nine clinical trials at various stages of completion. Despite this progress, durable graft function remains constrained by two major challenges: the absence of key islet microenvironment components, such as vasculature, extracellular matrix and supporting cell types and continued vulnerability to autoimmune and alloimmune rejection. METHODS & RESULTS: This review considers emerging technological approaches to overcome these barriers. Bioengineered niches, including multilineage organoids, functionalized hydrogels, decellularized matrices and bioprinting, aim to recreate the native islet microenvironment, while synthetic biology approaches, such as hypoimmune gene editing, CRISPR-based transcriptional control and stimulus-responsive survival circuits, seek to enhance grafts' resilience. Computational and single-cell approaches, including gene regulatory network analysis and digital twin frameworks, are beginning to provide predictive tools for benchmarking differentiation quality and forecasting graft outcomes. CONCLUSION: Together, these complementary strategies, potentially tailored to individual patients, represent a realistic path towards safer, more effective and durable β-cell replacement therapies for type 1 diabetes.